PAVmed Inc. Reports Revenue Growth to $22,000 but Incurred $8 Million Operating Loss in Q1 2026

PAVmed Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $22,000, a significant increase from $8,000 in the same period last year. Despite this growth in revenue, the company incurred an operating loss of $8.0 million, compared to a loss of $5.4 million in the first quarter of 2025. The increase in operating loss was primarily attributed to higher general and administrative expenses, which rose to $6.4 million from $4.4 million year-over-year, largely due to increased professional fees related to financing activities.

The company’s total assets increased to $45.4 million as of March 31, 2026, up from $38.8 million at the end of 2025. This growth was driven by a rise in cash reserves, which reached $6.5 million, compared to $1.5 million at the end of the previous fiscal year. PAVmed's liabilities also saw a notable decrease, dropping to $20.4 million from $16.5 million, primarily due to the refinancing of its Senior Secured Convertible Notes. The company’s stockholders’ equity increased to $25.0 million, reflecting a positive shift in its financial position.

Strategically, PAVmed has made significant advancements, including the hiring of Joseph Virgilio as Chief Business Officer for Medical Devices, aimed at overseeing the development of its medical device portfolio. The company also entered into a licensing agreement with Duke University for endoscopic imaging technology, which is expected to enhance its product offerings. Additionally, PAVmed secured a contract with the U.S. Department of Veterans Affairs to expand access to its EsoGuard test, furthering its market reach.

Operationally, PAVmed's engagement metrics indicate a steady trajectory, with the company focusing on expanding its Veris Cancer Care platform. The company reported a management fee income of $3.2 million, consistent with the previous year, and recognized an unrealized gain of $1.9 million on its investment in Lucid Diagnostics. However, PAVmed continues to face challenges, including recurring losses and negative cash flows, which raise concerns about its ability to sustain operations without additional financing.

Looking ahead, PAVmed anticipates ongoing challenges in achieving profitability and generating positive cash flows. The company plans to continue funding its operations through equity and debt financing while focusing on increasing revenues from its subsidiaries. Management has expressed confidence in its strategic initiatives but acknowledges the need for careful cost management and capital raising efforts to ensure long-term viability.